Table 1 Multivariable model on factors influencing the combined endpoint of severe infection/death during induction therapy in the training cohort.

From: Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Variable

Odds ratio

95% Confidence interval

p

Platelets (<150/nL)

2.05

1.28–3.33

0.003

ISS (stage III)

1.93

1.23–2.96

0.004

WHO performance status (>1)

1.83

1.10–3.08

0.021

Age (>60 years)

1.73

1.22–2.43

0.002

Calcium (>2.75 mmol/L)

1.59

0.82–2.84

0.174

BMI (>30.0 kg/m2)

1.29

0.83–1.93

0.258

Hemoglobin (<10.0 g/dl)

1.02

0.68–1.51

0.935

C-reactive protein (>5.0 mg/dL)

1.01

0.70–1.45

0.948

LDH (>ULN)

0.98

0.59–1.44

0.756

Sex (female)

0.81

0.57–1.15

0.238

White blood cell count (<4.0/nL)

0.78

0.46–1.26

0.324

Serum creatinine (>2.0 mg/dL)

0.70

0.38–1.27

0.249

GMMG-MM5

0.26

0.17–0.40

<0.001

GMMG-HD6

0.23

0.15–0.37

<0.001

  1. BMI body mass index, ISS International Staging System, LDH lactate dehydrogenase, GMMG German-speaking Myeloma Multicenter Group, ULN upper limit of normal, WHO World Health Organization.
Back to article page